President Trump said in his first in-person White House briefing since the election that the Covid-19 vaccine will be available to the U.S. except for New York, which he says has mishandled the virus and doesn8217;t trust his administration. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi
New York Gov. Andrew Cuomo “will have to let us know when he’s ready for it because otherwise, we can’t be delivering it to a state that won’t be giving it to its people immediately,” Trump said during a press conference from the White House Rose Garden.
“He doesn’t trust where the vaccine is coming from,” Trump added. “These are coming from the greatest companies anywhere in the world, greatest labs in the world, but he doesn’t trust the fact that it’s this White House, this administration, so we won’t be delivering it to New York until we have authorization to do so and that pains me to say that.”
Cuomo announced in late September that the state would form an independent task force of scientists, doctors and health experts that would review data from every Covid-19 vaccine approved by the U.S. Food and Drug Administration.
The governor said the state would independently review the vaccines after many questioned whether the White House was attempting to rush the approval process ahead of Election Day for political reasons.
Other states followed New York’s lead. California Gov. Gavin Newsom announced on Oct. 19 that the state wouldn’t distribute a vaccine until its own panel of experts reviewed the data to determine its safety. Washington, Oregon and Nevada joined California’s vaccine safety review group on Oct. 27, appointing their own experts to review any vaccine that receives federal approval and verify its safety before it’s made available to the public.
Over the past week, the U.S. coronavirus outbreak has worsened, with the nation reporting more than 150,000 new infections Thursday, according to data compiled by Johns Hopkins University. The seven-day average of daily new cases stands at 131,445, 32% higher than a week ago, according to a CNBC analysis of Hopkins data.
On Monday, Pfizer said that the Covid-19 vaccine it developed with German drugmaker BioNTech was 90% effective in a late-stage trial. Pfizer said its analysis evaluated 94 confirmed Covid-19 infections among the trial’s 43,538 participants. It said the case split between vaccinated individuals and those who received a placebo indicated a vaccine efficacy rate of above 90% at seven days after the second of the company’s two-dose vaccine.
Trump said Friday that it was an “unfortunate mistake” when Pfizer claimed earlier this week that it wasn’t part of Operation Warp Speed. While Pfizer did strike a deal with the U.S. government for vaccine doses in July, the company had been working on a vaccine for the coronavirus long before.
The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: https://www.cnbc.com/2020/09/29/the-news-with-shepard-smith-podcast.html?__source=youtube%7Cshepsmith%7Cpodcast
Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC